Drug
Aleplasinin clinical trials
Also written PAZ-417.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How studies write it
Studies that test it under each name
Development codes
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses aleplasinin is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Study of the Safety of PAZ-417 in Healthy Elderly AdultsTerminatedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00663065Written as PAZ-417
- Study Evaluating PAZ-417 in Cerebrospinal Fluid in Subjects With Alzheimer's DiseaseTerminatedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00739037Written as PAZ-417
- Study Evaluating the Safety, Tolerability and Activity of One Dose of PAZ-417 Given to Healthy Japanese SubjectsCompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00684710Written as PAZ-417
Codes
What other systems call aleplasinin · ClinicalTrials.gg INT017195
- UNII (FDA) LL56J87F3XALEPLASININConfirmed FDA, Wikidata
- Wikidata Q2640993aleplasininConfirmed FDA, Wikidata
- NCI Thesaurus C76071AleplasininOne source FDA
- DrugBank DB12635One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | LL56J87F3X | ALEPLASININ | Confirmed FDA, Wikidata |
| Wikidata | Q2640993 | aleplasinin | Confirmed FDA, Wikidata |
| NCI Thesaurus | C76071 | Aleplasinin | One source FDA |
| DrugBank | DB12635 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.